common.study.topics.clinical

Blood Markers of Early Pancreas Cancer

common.study.values.description

Blood Markers of Early Pancreas Cancer

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Diagnostic Test - Mixed Meal Tolerance Test

The goal of the test is to determine hormone secretion from the pancreas and small intestine in response to the mixed meal.

Diagnostic Test - Hemoglobin A1c

This test provides the average level of blood glucose over the last 3 months.

Diagnostic Test - Other exploratory blood biomarkers

Other exploratory blood biomarkers including cell free DNA and other markers in development

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer

common.study.values.clinical-trial-id

NCT03568630

participant.views.study.view.id

b8283e